The dissolution media were sampled at 30, 60, 120 and 180 minutes.For compositions that are oily in nature, the spray drying technique is commonly employed.
Derivatives of oil-soluble vitamins, such as vitamins A, D, E, K, etc., are also useful surfactants for the compositions of the present invention.As with the hydrophilic surfactants, lipophilic surfactants can be reaction mixtures of polyols and fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols.In particular, the present invention provides compositions and dosage forms including solid carriers for improved delivery of pharmaceutical active ingredients.The isolating effect is proportional to the thickness of the coating.Nucleoside phosphoramidates WO2011123668A2 Mar 31, 2011 Oct 6, 2011 Pharmasset, Inc.Other additives conventionally used in pharmaceutical compositions can be included, and these additives are well known in the art.
The characteristics of the final congealed product depend in part on the properties of the additives used.This is a list of recent changes to pages linked from a specified page (or to members of a specified category).The conversion of molten feed into powder is a single, continuous step.Method of treating and preventing secondary hyperparathyroidism US8333990 Sep 13, 2010 Dec 18, 2012 Abbott Laboratories Solid pharmaceutical dosage form US8337931 Jun 23, 2009 Dec 25, 2012 Virun, Inc.
A Dangerous Ingredient in Your SupplementsPolyglycerol esters of fatty acids are also suitable surfactants for the present invention.Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use US8361488 Apr 25, 2008 Jan 29, 2013 Cytochroma Inc.Typical solvents include ethanol, methanol, isopropanol, acetone, dichloromethane, trichloromethane and ethyl acetate.
Drug Dictionary - Virginia Oncology AssociatesSelected from data included with permission and copyrighted by First Databank, Inc.
Method of improving animal feeds using hydrolyzed lecithins US9180091 Dec 20, 2013 Nov 10, 2015 Therapeuticsmd, Inc.It is another object of the invention to provide solid pharmaceutical compositions capable of delivery a wide variety of pharmaceutical active ingredients.Preferred anionic surfactants include fatty acid salts and bile salts.At a minimum, the binder must be capable of wetting the surfaces of the particle being pelletized or granulated.For each of the three forms, material equivalent to 100 mg of progesterone was used for each dissolution run in 900 mL of isotonic pH 7.4 phosphate buffer.Compositions according to the present invention were prepared as follows.The production of small drops and liquid nitrogen cooling permit very rapid and uniform freezing of the material processed.
Solid carriers for pharmaceutical active ingredients offer potential advantages over micronized drugs, emulsions or solubilized formulations.Suitable PEG glycerol fatty acid esters are shown in Table 4.Likewise, various embodiments of the invention include a lipophilic component, which can be a lipophilic surfactant, including a mixture of lipophilic surfactants, a triglyceride, or a mixture thereof.Various embodiments of the invention, as described in more detail below, include a hydrophilic surfactant.
The particles are held together by solid bonds formed from the congealed melts.Liquid formulations present drug precipitation and packaging challenges, due to solvent evaporation.In addition, a certain amount of lot-to-lot variability is expected even for a single commercial surfactant product.
Additional additives and their levels, and selection of a primary coating material or materials will depend on the following properties.
Laxative - All Revolvy QuizzesWhen the solvent is aqueous-based, the components can be emulsified with an appropriate emulsifier, organic solvent, or a supercritical fluid.
Analysis of DEHYDRATION as a potential adverse side effect of MACROGOL.In addition, equipment design and processing variable also play an important role.Such diverse solid carriers can be blended in a dosage form to achieve a desired performance.The Eudragit series L, L-30D and S are insoluble in stomach and dissolve in the intestine.The following non-limiting Examples 13-28 illustrate compositions that can be prepared according to the present invention.Such solution or dispersion is then passed through a certain opening to achieve the desired shape, size, and other properties.In general, these triglycerides are readily available from commercial sources.The performance of acrylic polymers (primarily their solubility in biological fluids) can vary based on the degree and type of substitution.It is another object of the invention to provide solid pharmaceutical compositions having better protection of the upper gastrointestinal tract from untoward effects of the active ingredient.
The Eudragit series RL, NE, and RS are insoluble in the gastrointestinal tract but are permeable and are used primarily for extended release.Eudragit L100 is an acrylate polymer commercially available from Rohm Pharma.In general, these surfactants are hydrophilic, although several lipophilic surfactants of this class can be used.The hydrophilic surfactant can also be, or can include as a component, an ionic surfactant.The filtrates were then diluted in methanol to an appropriate concentration for a progesterone-specific HPLC assay.For compositions of the present invention that include a lipophilic additive, the lipophilic component can be a lipophilic surfactant or a triglyceride.Similarly, the choice of an appropriate binder for a given application is readily determined by one skilled in the art.Similarly, lipophilic surfactants are compounds having an HLB value less than about 10.Alternatively, the additives can be contained in the pharmaceutical composition but not part of the solid carrier itself.